Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Search results

Found 20 matches for

Peter Ratcliffe shares the prize with William Kaelin of the Dana-Farber Cancer Institute and Gregg Semenza of John Hopkins University for their research on cellular responses to hypoxia.

From mutation to malignancy: mapping early events in kidney cancer

A new study from the Ratcliffe group examines how distinct HIFα isoforms shape the way VHL mutations lead to kidney cancer.

Ludwig researchers identify new role for nitric oxide in oxygen sensing

Recent research by the Ratcliffe lab at Ludwig Oxford, led by Tom Keeley, has revealed a new mechanism through which nitric oxide (NO) controls the destruction of selected proteins in response to oxygen levels.

Oxygen chemosensitivity in chromaffin cells programmed by HIF-2α

Members of the Ratcliffe research group (Maria Prange-Barczynska, Holly Jones and Yoichiro Sugimoto) show that activation of HIF-2α is sufficient to confer oxygen chemosensitivity in chromaffin cells.

Protein Stability may be defined by N-terminal cysteine acetylation and oxidation patterns

The Ratcliffe group investigate the relationship between ADO-catalysed oxidation and NatA-catalysed acetylation of a broad range of protein sequences with N-terminal cysteines. This relationship has implications for O2-dependent protein stability and the hypoxic response.

Ludwig Oxford at 2024 AACR

Ludwig Oxford staff and students alike share their research in San Diego at the 2024 AACR Annual Meeting

International Women's Day within Ludwig Oxford

The 8th March annually celebrates Women's achievements and we are delighted to celebrate the women researchers, students and staff within Ludwig Oxford

Factor-inhibiting HIF deficiency is found to create a tumour-promoting immune microenvironment

A collaborative study by the Lu and Ratcliffe research groups has found that the tumour-promoting immune microenvironment can be created by a deficiency in factor-inhibiting HIF.

Comparative analysis of ADO and PHD enzymes allows researchers to better understand their co-evolution and integration into oxygen homeostasis mechanisms

Ludwig Oxford’s Peter Ratcliffe and Tom Keeley have undertaken a comparative analysis of a number of enzymes involved in the adaption of cells to oxygen level changes.

HIF and AHR transcription factors interact in kidney carcinomas raising the potential for effective combination therapy

Ludwig Oxford’s David Mole and Peter Ratcliffe show interaction between transcription factors HIF and AHR, indicating a combined approach to therapy may provide greater efficacy for cancer treatment.

Ludwig’s Tammie Bishop awarded Associate Professorship

Congratulations to Tammie Bishop, who is made associate professor at the University of Oxford.

Pan-cancer gene signature provides insights into HIF pathway activation

Researchers from David Mole’s and Peter Ratcliffe’s laboratories establish a HIF metagene for studying hypoxia pathways.

Dr Tammie Bishop receives The Physiology Society’s R Jean Banister Prize

Congratulations to Dr Tammie Bishop who will give the R Jean Banister Prize Lecture Series in 2023

Ludwig Oxford retreat 2022 – a recap

On 13-14th June 2022, the Oxford Branch of the Ludwig Institute for Cancer Research held their annual retreat to discuss key scientific advances within the Branch and beyond.

Ludwig Oxford at AACR 2022

Several Ludwig Oxford researchers present at the American Association for Cancer Research (AACR) Annual Meeting.

Developmental origins of inherited cancers bearing mutations in the oxygen-sensing pathway

Dr Tammie Bishop’s and Professor Sir Peter Ratcliffe’s groups shed light on the developmental origins of inherited cancers with mutations in the HIF pathway.

HIFs inhibit SARS-CoV-2 infection of lung epithelial cells

Activation of hypoxia inducible factors (HIFs) by either hypoxia or drug treatment inhibits SARS-CoV-2 entry and replication in lung epithelial cells, raising the potential of using clinically licensed HIF activators to prevent and/or treat COVID-19.

Anti-cancer HIF-2 inhibition affects the hypoxic ventilatory response

Researchers from Dr Tammie Bishop’s and Prof Sir Peter Ratcliffe’s laboratories show that an anti-cancer HIF inhibitor impairs the normal ventilatory response to low oxygen.

Support for the pathway tuning model of cancer

Researchers from David Mole’s and Peter Ratcliffe’s labs investigate a model for cancer evolution using renal clear cell carcinoma.

Nobel Prize 2019 awarded to Sir Peter Ratcliffe

Ludwig Oxford’s Professor Sir Peter Ratcliffe receives the Nobel Prize in physiology or medicine at an awards ceremony in Stockholm.

Ludwig Oxford’s Sir Peter Ratcliffe wins the Nobel Prize in medicine

Peter Ratcliffe shares the prize with William Kaelin of the Dana-Farber Cancer Institute and Gregg Semenza of John Hopkins University for their research on cellular responses to hypoxia.

Similar stories

From mutation to malignancy: mapping early events in kidney cancer

A new study from the Ratcliffe group examines how distinct HIFα isoforms shape the way VHL mutations lead to kidney cancer.

Ludwig researchers identify new role for nitric oxide in oxygen sensing